These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255 [TBL] [Abstract][Full Text] [Related]
44. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Steuer CE; Wu C; Lawson DH; Kudchadkar R; Master VA; El-Rayes B; Ramalingam SS; Owonikoko TK; Harvey RD BMC Cancer; 2019 Aug; 19(1):857. PubMed ID: 31464611 [TBL] [Abstract][Full Text] [Related]
45. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation. T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286 [TBL] [Abstract][Full Text] [Related]
46. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R; Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760 [TBL] [Abstract][Full Text] [Related]
47. Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study. Wang H; Liu W; Zhao Y; Hu H; Zhang B; Yang S Asia Pac J Clin Oncol; 2023 Oct; 19(5):e291-e299. PubMed ID: 36572661 [TBL] [Abstract][Full Text] [Related]
48. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome. Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T Front Immunol; 2021; 12():651086. PubMed ID: 34248939 [TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. Kanani A; Veen T; Søreide K Br J Surg; 2021 Dec; 108(12):1417-1425. PubMed ID: 34694371 [TBL] [Abstract][Full Text] [Related]
51. Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis. Zhang X; Yang Z; An Y; Liu Y; Wei Q; Xu F; Yao H; Zhang Z World J Surg Oncol; 2022 Mar; 20(1):93. PubMed ID: 35331250 [TBL] [Abstract][Full Text] [Related]
52. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis. Petrelli F; Ghidini M; Ghidini A; Tomasello G JAMA Oncol; 2020 Jul; 6(7):1068-1071. PubMed ID: 32407439 [TBL] [Abstract][Full Text] [Related]
53. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer. Xiao BY; Zhang X; Cao TY; Li DD; Jiang W; Kong LH; Tang JH; Han K; Zhang CZ; Mei WJ; Xiao J; Pan ZZ; Li YF; Zhang XS; Ding PR J Natl Compr Canc Netw; 2023 Jan; 21(1):60-66.e5. PubMed ID: 36630898 [TBL] [Abstract][Full Text] [Related]
54. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. Gallois C; Emile JF; Kim S; Monterymard C; Gilabert M; Bez J; Lièvre A; Dahan L; Laurent-Puig P; Mineur L; Coriat R; Legoux JL; Hautefeuille V; Phelip JM; Lecomte T; Sokol H; Capron C; Randrian V; Lepage C; Lomenie N; Kurtz C; Taieb J; Tougeron D Dig Liver Dis; 2021 Oct; 53(10):1254-1259. PubMed ID: 34215534 [TBL] [Abstract][Full Text] [Related]
55. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France. Roset M; Amonkar M; Patel R; Lara N; Kothari S Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060 [TBL] [Abstract][Full Text] [Related]
56. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Li J; Wu C; Hu H; Qin G; Wu X; Bai F; Zhang J; Cai Y; Huang Y; Wang C; Yang J; Luan Y; Jiang Z; Ling J; Wu Z; Chen Y; Xie Z; Deng Y Cancer Cell; 2023 Jun; 41(6):1152-1169.e7. PubMed ID: 37172580 [TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan. Sugiura K; Hiratsuka H; Oshima G; Aiko S Jpn J Clin Oncol; 2023 Jul; 53(8):691-697. PubMed ID: 37259600 [TBL] [Abstract][Full Text] [Related]
58. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653 [TBL] [Abstract][Full Text] [Related]
59. Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer. van der Heide DM; Turaga KK; Chan CHF; Sherman SK J Surg Res; 2021 Oct; 266():104-112. PubMed ID: 33989889 [TBL] [Abstract][Full Text] [Related]